First human test of Alzheimer’s nasal vaccine in the United States

Washington, November 18th : .

The first ever clinical trial will be conducted by Brigham and Womens Hospital in the United States to determine the safety and effectiveness of the nasal vaccine that is designed to slow down or prevent the development of Alzheimers Disease (AD)Protollin is an intranasal investigational immunomodulator that stimulates your immune system.

Protollin, which is made of bacteria-derived proteins, has been safely used in humans to adjuvant other vaccines.Howard L.Weiner MD, who is co-director at the Ann Romney Center for Neurologic Diseases, said that the immune system plays an important role in neurologic disorders.There has been increasing evidence for 20 years that beta amyloid elimination is a function of the immune system.

The vaccine uses a new arm of the immune to treat AD," said Tanuja Chitnis (Professor of Neurology, Brigham).Protollin activates white blood cells in lymph nodes at the back and sides of the neck.

This allows them to move to the brain to clear beta amyloid plaques.Participants will be aged between 60-85 years old and have early symptoms of AD.Participants will be administered two doses of nasal vaccine, one each week.Weiner stated that if the vaccine is safe, it may be a non-toxic treatment to people suffering from Alzheimers.

It could also help people who are at high risk of developing Alzheimers.Phase I will test the vaccines safety and acceptability.

By examining cell surfaces, gene profiles and functional assays, the research team will assess how nasal Protollin affects participants immune responses, in particular its effect on white blood cells.According to the statement, this trial marks also the end of twenty years worth of hospital research.

Weiner stated, "The first human nasal vaccination trial for Alzheimers disease has been launched.Its a significant milestone.

Its thrilling that after more than 20 years of work in preclinical and clinical settings, we are finally able to take the key step towards clinical translation by conducting this first human study." rvt/b #human #Alzheimers #nasal #vaccine.